Food and Drug Administration recently
approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who
have received at least two prior therapies, including treatment with Velcade
(bortezomib) and an immunomodulatory therapy. U.S.
A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones. The bone marrow is where normal blood cells are produced.
More information on carfilzomib : http://chembl.blogspot.be/2012/07/new-drug-approvals-2012-pt-xv.html